Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Mild Cognitive Impairment
- Sponsor
- Beth Israel Deaconess Medical Center
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Number of participants with adverse events
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The investigators are investigating the benefits of a mind/body intervention, Mindfulness Based Stress Reduction, for adults with Mild Cognitive Impairment.
Detailed Description
We propose a prospective, randomized controlled pilot trial assessing the feasibility and safety of a study investigating mindfulness based stress reduction (MBSR) as an intervention in adults with Mild Cognitive Impairment (MCI). We are assessing safety and feasibility of this intervention, as well as using neuroimaging (fMRI) to assess improved connections in the default mode network. We will also be assessing the impact of this intervention on cognitive function and measures of well-being.
Investigators
Rebecca Wells
Instructor of Medicine
Beth Israel Deaconess Medical Center
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of MCI\* made by a neurologist (through history, physical exam and neuropsychological testing)
- •Memory complaint, corroborated by an informant
- •Abnormal memory function documented by memory testing \<1.5 standard deviation below normative controls (assessed with the Wechsler Memory scale IV\[114\], Logical Memory subtest, or an equivalent test)
- •Normal general cognitive function
- •Mini-Mental Status Exam (MMSE) score of \>24 out of 30
- •No/minimal impairment in activities of daily living
- •Not sufficiently impaired, cognitively or functionally, to meet the National Institute of Neurological and Communicative Disease and Stroke/Alzheimer's Disease and Related Disorders Association criteria for AD
- •Clinical Dementia Rating (CDR total score of 0.5, with at least 0.5 on memory subscale
- •No history of significant cerebrovascular disease based on Modified Hachinski score ≤ 4
- •Hamilton Depression Rating Scale score ≤12 (to rule out depression as a contributing cause of cognitive decline)
Exclusion Criteria
- •Actively practicing meditation and/or yoga or have taken a meditation/yoga class in the last 6 months
- •Any major systemic illness or unstable medical condition which could lead to difficulty complying with the protocol, including the diagnosis of major depression
- •On psychoactive medications (antidepressants with anticholinergic effects, ie. tricyclic antidepressants, neuroleptics, chronic anxiolytics, sedative hypnotics, other anticholinergics); participants may take stable doses (stable for at least 6 months) of low doses of psychoactive medicines (i.e. ≤ 1mg klonipin/day or ≤25mg Benadryl/day)
- •Psychotic features, agitation, or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol
- •History of alcohol or substance abuse or dependence within the past 2 years
- •Any history of brain lesions or major head trauma
- •Participant unable/unwilling to follow the protocol or return for follow-up
- •Investigational agents prohibited at entry and for the duration of the trial
- •Participation in other clinical studies involving neuropsychological measures being collected more than one time per year
- •MRI exclusions: presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
Outcomes
Primary Outcomes
Number of participants with adverse events
Time Frame: 8 weeks
Participants will inform us if they have had any adverse events during the study period and we will track to see if any occur for any of the participants
Feasibility: 85% completion
Time Frame: 8 weeks
To judge the feasibility of the trial, recruitment efforts will be documented in terms of number of eligible patients approached, number who declined participation, number successfullyl recruited, and number who completed the trial. The trial will be feasible if 85% (the absolute percentage of patients) complete the trial.
Secondary Outcomes
- Change in fMRI Resting state(Change from baseline to 8 weeks)
- Change in Cognition(Change from baseline to 8 weeks)
- Change in Measures of "well-being"(Change from baseline to 8 weeks)
- Qualitative Improvements(8 weeks)